Kenvue (KVUE) – Research Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of Kenvue (NYSE: KVUE) recently:

• 2/3/2025 – Kenvue had its “sector perform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $24.00 price target on the stock.
• 1/17/2025 – Kenvue had its price target lowered by analysts at Barclays PLC from $23.00 to $21.00. They now have an “equal weight” rating on the stock.
• 1/16/2025 – Kenvue had its price target lowered by analysts at UBS Group AG from $24.00 to $23.00. They now have a “neutral” rating on the stock.
• 1/15/2025 – Kenvue had its price target lowered by analysts at Citigroup Inc. from $25.00 to $21.00. They now have a “neutral” rating on the stock.
• 1/6/2025 – Kenvue was upgraded by analysts at Piper Sandler from a “neutral” rating to an “overweight” rating. They now have a $26.00 price target on the stock, up previously from $21.00.
• 12/12/2024 – Kenvue was upgraded by analysts at Barclays PLC to a “hold” rating.
• 12/12/2024 – Kenvue was downgraded by analysts at Deutsche Bank Aktiengesellschaft from a “buy” rating to a “hold” rating. They now have a $24.00 price target on the stock, down previously from $25.00.
• 12/9/2024 – Kenvue was upgraded by analysts at Royal Bank of Canada from a “hold” rating to a “moderate buy” rating.

Kenvue Price Performance

Kenvue stock traded down $0.17 during midday trading on Monday, hitting $21.13. 3,925,876 shares of the company’s stock were exchanged, compared to its average volume of 11,377,387. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46. The stock has a 50-day moving average price of $21.90 and a two-hundred day moving average price of $21.92. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The company has a market cap of $40.50 billion, a P/E ratio of 38.41, a PEG ratio of 2.05 and a beta of 1.45.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The firm had revenue of $3.90 billion during the quarter, compared to analysts’ expectations of $3.92 billion. During the same period in the prior year, the business earned $0.31 EPS. The company’s revenue for the quarter was down .4% compared to the same quarter last year. On average, equities research analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be given a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 3.88%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s payout ratio is 149.09%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Grove Bank & Trust raised its position in Kenvue by 438.4% during the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after purchasing an additional 947 shares during the last quarter. Riverview Trust Co bought a new position in shares of Kenvue in the 3rd quarter worth approximately $30,000. Geneos Wealth Management Inc. bought a new position in shares of Kenvue in the 4th quarter worth approximately $29,000. Ashton Thomas Securities LLC bought a new position in shares of Kenvue in the 3rd quarter worth approximately $35,000. Finally, Fortitude Family Office LLC raised its position in shares of Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after acquiring an additional 777 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.